MATERIALS AND METHODS

Patients

CAEBV infection was defined as 1) persistent or recurrent symptoms related to EBV infection for more than three months; 2) high EBV genome levels in affected tissues or peripheral blood; 3) chronic illness that could not be explained by other known disease processes at diagnosis, and 4) no specific underlying immunological abnormality.7

To identify EBV-positive systemic T-cell LPD of childhood based on the 2008 WHO classification, all patients with EBV-positive hemophagocytic syndrome presenting at our institution were enrolled in the present study. Patient inclusion was based on the fulfillment of the diagnostic criteria for HLH-2004 in addition to the presence of a high viral load in the tissues or peripheral blood.3

The surgical pathology database of Samsung Medical Center from 1994 to 2012 was screened with keywords including "CAEBV," "EBV," and "hemophagocytosis." Of the 96 cases retrieved using "EBV" and "hemophagocytosis" as keywords, 84 patients were excluded because LPD had arisen in immunocompromised patients, such as those receiving organ transplantation or patients with congenital immune deficiency syndrome. Fifteen patients were diagnosed with CAEBV infection, and 12 patients had paraffin blocks available for examination. Among the remaining 12 patients, seven had paraffin blocks available for examination and were enrolled in the present study. Formalin-fixed paraffin-embedded blocks of liver, bone marrow, and lymph node tissues were used for further investigation.

Immunohistochemistry

Immunohistochemical analysis was performed on the paraffin sections using monoclonal and polyclonal antibodies to detect lineage-specific or lineage-characteristic antigens, including CD3 (Dakopatts, Copenhagen, Denmark), CD20 (Novocastra, Newcastle upon Tyne, UK), CD56 (Novocastra), CD4 (Novocastra), and CD8 (Novocastra).

T-cell receptor (TCR) gene rearrangement

For the polymerase chain reaction (PCR) amplification of the TCR γ locus, DNA was extracted from the paraffin-embedded formalin-fixed tissues with the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). Conventional PCR followed by single-stranded conformational polymorphism analysis was performed, as previously described.8 When conventional PCR for TCR γ genes produced negative results, further analysis was performed using the TCR β and γ primers, according to the recommendations of the BIOMED-2 protocols (Invivoscribe, San Diego, CA, USA).9

RESULTS

All patients (12 males and eight females) were Korean, ranging from 4 to 61 years of age.

EBV-positive hemophagocytic syndrome

TCR gene rearrangement

TCR gene rearrangement analysis revealed monoclonality in two patients (28.6%) and polyclonality in four patients (57.1%) (Fig. 1). The analysis of one patient failed because the DNA quality was poor. Two patients with T-cell monoclonality were classified as suffering systemic T-cell LPD and the remaining patients as suffering EBV-positive HLH.

Clinicopathological findings of systemic T-cell LPD and EBV-positive HLH

Of the two patients with systemic T-cell LPD, one was a young female and the other an adult male. The EBV-positive HLH patients included two children, two young adults, and one elderly adult, with ages ranging from 4 to 61 years (median, 20 years). The clinicopathological findings for the two conditions were similar, and almost all patients had acute-onset fever. Their symptoms included lymph node enlargement and hepatosplenomegaly. The duration of the symptoms was two months in patients with systemic T-cell LPD and ranged from three days to one month (median, 1 month) in EBV-positive HLH patients. Two patients with systemic T-cell LPD received chemotherapy but died after two and three months, respectively. Among the five patients with EBV-positive HLH, four received chemotherapy or steroid and died after a median period of one month, whereas the one patient treated with the HLH-2004 regimen recovered completely and was alive at the final follow-up. The EBV load in the peripheral blood was analyzed using whole blood, and the loads during the clinical course are shown in Table 1. The levels were variable, and two patients with EBV-positive HLH showed high viral loads in their peripheral blood.

Biopsies were obtained from the bone marrow of six patients, lymph nodes of two patients, liver of one patient, and spleen of one patient. In the bone marrow, liver, and spleen samples, the number of lymphocytes was slightly increased and showed mild to equivocal atypia. Hemophagocytic histiocytosis was observed in all patients. The lymph node biopsies from patient 1 (systemic T-cell LPD) and patient 3 (EBV-positive HLH) demonstrated diffuse effacement of the nodal architecture by the infiltration of monotonous medium-sized atypical lymphocytes (Fig. 2). The lymphocytes had hyperchromatic nuclei and irregular nuclear contours. At the first liver biopsy of patient 3, EBV-infected cells were small to medium size and showed mild to equivocal atypia (Fig. 3A, B). After three months, the lymph nodes of patient 1 were effaced and infiltrated by medium-sized atypical EBV-positive lymphocytes (Fig. 3C-F). On initial examination, the histological findings suggested neoplastic proliferation, but patient 3 displayed polyclonality according to the TCR gene rearrangement (Table 1). The bone marrow of the two patients showed similar findings to the observations in the lymph nodes.

The phenotype of the infiltrated cells was CD3-positive, CD20-negative, and CD56-negative in all cases. Systemic T-cell LPD showed mixed CD4- or CD8-positive cells. EBV-positive HLH was CD8-positive T-cell dominant in three patients and CD4-positive T-cell dominant in two patients. In situ hybridization used to detect EBV in biopsy tissues using the EBV-encoded early RNA 1 probe showed the presence of EBV-infected cells in six of seven patients (Fig. 2). In one patient, in situ hybridization failed to detect EBV because the tissue was improperly fixed. The numbers of EBV DNA copies in the peripheral blood varied, ranging up to 5,810 copies/µL.

CAEBV infection

The CAEBV group consisted of 12 patients (eight males and four females), with ages ranging from 10 to 59 years (median, 21 years) (Table 2). Nine patients were children or young adults, one patient was elderly, and their clinical manifestations varied. Eight patients presented with hepatosplenomegaly and lymphadenopathy, and six patients complained of fever. Mosquito-bite hypersensitivity was observed in four children, and three patients had NK lymphocytosis. One child experienced hydroa vacciniforme-like eruption. Some patients manifested unusual clinical findings, such as bowel perforation, immunoglobulin A nephropathy, choreic movement, and brain infarction. Biopsies of the bone marrow, skin, gastrointestinal tract, or lung were performed. The histology varied according to the site of biopsy. EBV-positive lymphocytes were scattered, and infiltrated lymphocytes were predominantly small and devoid of atypia (Fig. 4). Hemophagocytic histiocytosis was found in seven of 11 bone marrow tissues. On immunohistochemistry, CD4-positive T-cells were dominant in three patients and CD8-positive cells were dominant in three patients.

Monoclonality was detected in three of the six patients in whom PCR analysis of the TCR gene was successful. Among the three polyclonal patients, one was CD56-positive, with a skewed killer cell immunoglobulin-like receptor (KIR) phenotype, suggesting monoclonal NK-cell proliferation. Among the three patients with polyclonal T-cell proliferation, two were alive and one was alive 30 months after diagnosis. Of the three patients with monoclonal T-cell proliferation, two patients with monomorphic histology died of their disease after ten months and seven months, respectively, and one patient with polymorphic histology had persistent disease six months after diagnosis. The median survival was 18 months. Comparison of patient survival according to clonality was not statistically meaningful because of the limited number of patients included in the study, but monoclonal patients tended to have poorer prognosis.

DISCUSSION

EBV-positive HLH is a clinical entity described in the literature that includes a wide spectrum of illnesses, ranging from EBV-associated reactive polyclonal lymphoproliferation to monoclonal disease.10-12 EBV-associated HLH can be divided into three evolutional stages. The innate immune response phase in the first week of EBV infection is followed by the T-cell activation stage in the second week, which is followed later by the macrophage activation stage. During the last evolutionary phase, a substantial percentage of patients may progress to monoclonal T-cell LPD with or without an abnormal karyotype, which is equivalent to EBV-positive systemic T-cell LPD of childhood.13,14 In vitro studies have suggested that the tumor necrosis factor (TNF) receptor secreted by EBV-infected T-cells and the TNF-receptor-associated factors/nuclear factor-κB/extracellular signal-related kinase pathway activated by the EB viral protein, LPM-1, play a role in the progression to T-cell lymphoma.15

The "EBV-positive systemic T-cell LPD of childhood" in the 2008 WHO classification corresponds to the neoplastic stage of EBV-positive HLH. However, the separation of systemic T-cell LPD from EBV-positive HLH based on clonality raises two issues: difficult diagnosis due to the technical limitations of clonality assessment, and the clinical impact of clonality on EBV-positive NK- or T-cell LPD.

The clonality of EBV-infected LPD can be determined by various methods, including TCR gene rearrangement, cytogenetic studies, and investigation of the terminal repeats of the EBV genome. TCR gene rearrangement, detected by conventional PCR analysis or Southern blot hybridization, is inadequate to examine the clonality of T-cell EBV-infected LPD because of its low sensitivity. EBV-infected cells defined as polyclonal by TCR analysis can be monoclonal based on EBV terminal repeat analysis or cytogenetic analysis. The sensitivity of the recently developed BIOMED-2 assay is superior to the conventional PCR assay.16 In addition to low sensitivity, a TCR gene rearrangement study is disadvantageous because it cannot be used for EBV-positive HLH of NK-cell types. EBV usually infects B-cells and uncommonly T-cells, but NK-cells can also be infected. A recent study by Kimura et al.17 demonstrated that a minor proportion of EBV-positive HLH is actually an NK-cell disorder. Human NK-cells use a sophisticated system of inhibitory and stimulatory receptors of the KIR gene family, which are expressed in a clonally distributed manner. NK-cell KIR gene phenotyping can help determine the clonality of NK-cells,18 but fresh samples are required. Thus, this technique has limited utility in the analysis of paraffin-embedded tissues. Analysis of the EBV terminal repeat may be the most sensitive method because it can be applied in T-, B- and NK-cell disorders. However, EBV clonality is difficult to analyze with routine diagnostic biopsies because large amounts of freshly sampled DNA for Southern blot hybridization are required; chromosomal studies share the same issue.

The clonality of EBV-positive HLH has been reported in a few studies from Asia.12,19,20 A study using conventional PCR reported monoclonal TCR gene rearrangements in ten of 30 adult patients and immunoglobulin gene rearrangements in eight of the same 30 patients.19 The study by Imashuku et al.,12 who analyzed the EBV terminal repeat with Southern blotting, revealed a monoclonal pattern in 20 of 24 patients, a biclonal pattern in two patients, and a polyclonal pattern in two patients. In their study, the TCR gene rearrangement was monoclonal in 15 of 25 patients and polyclonal in ten of the same 25 patients. Clonal cytogenetic abnormalities were observed in seven of 23 patients.12 Recently, Matsuda et al.20 analyzed the TCR gene with the BIOMED-2 protocol, the most recent and advanced technique for gene rearrangement studies and found at all six children with HLH showed a clonal band. According to the above-mentioned studies, a significant proportion of EBV-positive HLH is a clonal disease that would be classified as STLPD of childhood by the current WHO classification.

In previous studies that analyzed the clonality of EBV and proliferating cells in EBV-positive HLH, clonality itself apparently had no clinical impact on patient outcome.19 Imashuku et al.12 reported that the clonality of T- and B-cells has no prognostic significance, whereas all patients with cytogenetic abnormalities experience an aggressive clinical course. The clinical significance of a clonal karyotypic abnormality was also reported in other studies.21 During the transformation from benign reactive lymphoid proliferation to overt neoplastic disease, a small clone of EBV-infected T- or NK-cells may emerge11 and transform into more malignant cells as genetic changes accumulate. Early clonal LPD in this neoplastic transformation may show a similar treatment response to polyclonal EBV-positive HLH, but overt malignant lymphoma with chromosomal abnormality will behave differently.

In terms of patient management, the clinician may use chemotherapy as the initial treatment when the patient is diagnosed with systemic T-cell LPD; however, in patients with EBV-positive HLH, the clinical selection of a therapeutic modality depends on the risk factors for EBV-positive HLH: persistently high EBV genome copy number in the serum, acute fulminant or CAEBV infection, abnormal karyotype, and an association with hereditary disease.22,23 Currently, successful therapies such as conservative/mild treatments without etoposide, HLH-94/2004-type treatment with etoposide, and very aggressive lifesaving measures, including hematopoietic stem cell transplantation, are administered to HLH patients,2,3 illustrating a survival rate greater than 75%.24 In our series, one child treated with the HLH-2004 regimen recovered completely and is alive, whereas other patients who received chemotherapy died. Similarly, two patients with STLPD died despite chemotherapy. Because STLPD does not usually respond to chemotherapy, research for new treatments is needed.

CAEBV infection is synonymous with chronic symptomatic EBV infection. After a primary EBV infection, the majority of patients recover completely, but a substantial proportion of patients develop CAEBV infection, which is currently incurable. The clinical activity of the disease may depend on the balance between the host immune function and the virus. The usual symptoms are fever, hepatic dysfunction, lymphadenopathy, or splenomegaly; however, as shown in the present study, patients often present with unusual clinical manifestations, such as chorea, cerebral hemorrhage, generalized myositis, glomerulonephritis, and pulmonary hypertension.25,26 The disease develops in children and adolescents but can also develop in young adults and elderly patients, although with a lower frequency.17,27

CAEBV infection is almost always accompanied by varying degrees of lymphoproliferation. In the Asian population, CAEBV infection mainly involves T- or NK-cells. The clonality of EBV and EBV-infected T- or NK-cells varies and may be polyclonal, oligoclonal, or monoclonal. As the disease progresses from polyclonal lymphoproliferation to monoclonal disease, histological atypia increases.28 Ohshima et al.28 proposed the categorization of CAEBV infection into three groups, polymorphous and polyclonal, polymorphous and monoclonal, or monomorphic and monoclonal, based on the clonality and histological changes. In the series reported by Ohshima et al.,28 eight of 48 patients with CAEBV infection were polyclonal for TCR gene rearrangement, and the infiltrated cells displayed polymorphic histomorphology; 15 patients showed polymorphic morphology and biclonal or monoclonal TCR gene rearrangement; and 25 patients showed monomorphic histomorphology and monoclonal TCR gene rearrangement. Patients with the monomorphic and monoclonal type of CAEBV infection had poorer prognosis than patients with polymorphic polyclonal or polymorphic monoclonal disease. The survival of the polymorphic polyclonal and polymorphic monoclonal groups did not differ significantly.28 According to the 2008 WHO classification, systemic T-cell LPD corresponds to the polymorphic monoclonal and monomorphic monoclonal groups of CAEBV infection. Despite the limitations of a small sample size in our study, the patients with monoclonal CAEBV infection tended to have a poorer prognosis.

In conclusion, EBV-positive HLH and systemic T-cell LPD share similar clinicopathological findings and may constitute a continuous spectrum of acute EBV-associated T- or NK-cell proliferative disorders. The distinction of EBV-positive T-cell LPD from EBV-positive HLH may be difficult during routine diagnoses due to technical limitations of clonality assessment. The clinical impact of clonality in acute EBV-associated T- or NK-cell proliferative disorders is unclear, whereas monoclonal CAEBV infection disease tends to have a worse prognosis.

Notes

No potential conflict of interest relevant to this article was reported.

References

• 1. Rickinson AB. Chronic, symptomatic Epstein-Barr virus infections. Immunol Today 1986; 7: 13–14. ArticlePubMed
• 2. Henter JI, Aricò M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol 1997; 28: 342–347. PMID: 9121398. ArticlePubMed
• 3. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124–131. PMID: 16937360. ArticlePubMed
• 4. Quintanilla-Martinez L, Kimura H, Jaffe ES. In : Swerdlow SH, Campo E, Harris NL, eds. EBV-positive T-cell lymphoproliferative disorders of childhood. WHO classification of tumours of haematopoietic and lymphoid tissues. 2008; 4th ed. Lyon: IARC Press, 278–280.
• 5. Quintanilla-Martinez L, Kumar S, Fend F, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000; 96: 443–451. PMID: 10887104. ArticlePubMedPDF
• 6. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187: 527–533. PMID: 12599068. ArticlePubMed
• 7. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 2005; 80: 64–69. PMID: 16138335. ArticlePubMed
• 8. Signoretti S, Murphy M, Cangi MG, Puddu P, Kadin ME, Loda M. Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. Am J Pathol 1999; 154: 67–75. PMID: 9916920. ArticlePubMedPMC
• 9. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317. PMID: 14671650. ArticlePubMed
• 10. Wada T, Kurokawa T, Toma T, et al. Immunophenotypic analysis of Epstein-Barr virus (EBV)-infected CD8(+) T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis. Eur J Haematol 2007; 79: 72–75. PMID: 17532761. ArticlePubMed
• 11. Lin MT, Chang HM, Huang CJ, et al. Massive expansion of EBV+ monoclonal T cells with CD5 down regulation in EBV-associated haemophagocytic lymphohistiocytosis. J Clin Pathol 2007; 60: 101–103. PMID: 17213357. ArticlePubMedPMC
• 12. Imashuku S, Hibi S, Tabata Y, et al. Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases. Leuk Lymphoma 2000; 37: 577–584. PMID: 11042518. ArticlePubMed
• 13. Su IJ, Wang CH, Cheng AL, Chen RL. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk Lymphoma 1995; 19: 401–406. PMID: 8590839. ArticlePubMed
• 14. Chen RL, Su IJ, Lin KH, et al. Fulminant childhood hemophagocytic syndrome mimicking histiocytic medullary reticulosis: an atypical form of Epstein-Barr virus infection. Am J Clin Pathol 1991; 96: 171–176. PMID: 1650532. ArticlePubMed
• 15. Chuang HC, Lay JD, Hsieh WC, Su IJ. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci 2007; 98: 1281–1287. PMID: 17627615. ArticlePubMed
• 16. Liu H, Bench AJ, Bacon CM, et al. A practical strategy for the routine use of BIOMED-2 PCR assays for detection of B- and T-cell clonality in diagnostic haematopathology. Br J Haematol 2007; 138: 31–43. PMID: 17555445. ArticlePubMed
• 17. Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012; 119: 673–686. PMID: 22096243. ArticlePubMed
• 18. Sawada A, Sato E, Koyama M, et al. NK-cell repertoire is feasible for diagnosing Epstein-Barr virus-infected NK-cell lymphoproliferative disease and evaluating the treatment effect. Am J Hematol 2006; 81: 576–581. PMID: 16823820. ArticlePubMed
• 19. Ahn JS, Rew SY, Shin MG, et al. Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 2010; 85: 719–722. PMID: 20652965. ArticlePubMed
• 20. Matsuda K, Nakazawa Y, Yanagisawa R, Honda T, Ishii E, Koike K. Detection of T-cell receptor gene rearrangement in children with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis using the BIOMED-2 multiplex polymerase chain reaction combined with GeneScan analysis. Clin Chim Acta 2011; 412: 1554–1558. PMID: 21570959. ArticlePubMed
• 21. Ito E, Kitazawa J, Arai K, et al. Fatal Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with clonal karyotype abnormality. Int J Hematol 2000; 71: 263–265. PMID: 10846833. PubMed
• 22. Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol 2011; 33: 35–39. PMID: 21088619. ArticlePubMed
• 23. Imashuku S, Kuriyama K, Sakai R, et al. Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med Pediatr Oncol 2003; 41: 103–109. PMID: 12825212. ArticlePubMed
• 24. Imashuku S, Teramura T, Tauchi H, et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica 2004; 89: 183–188. PMID: 15003893. PubMed
• 25. Kano K, Yamada Y, Sato Y, Arisaka O, Ono Y, Ueda Y. Glomerulonephritis in a patient with chronic active Epstein-Barr virus infection. Pediatr Nephrol 2005; 20: 89–92. PMID: 15503175. ArticlePubMed
• 26. Uchiyama T, Arai K, Yamamoto-Tabata T, et al. Generalized myositis mimicking polymyositis associated with chronic active Epstein-Barr virus infection. J Neurol 2005; 252: 519–525. PMID: 15742118. ArticlePubMed
• 27. Isobe Y, Aritaka N, Setoguchi Y, et al. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma. J Clin Pathol 2012; 65: 278–282. PMID: 22247563. ArticlePubMed
• 28. Ohshima K, Kimura H, Yoshino T, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 2008; 58: 209–217. PMID: 18324913. ArticlePubMed

Fig. 1

T-cell receptor (TCR) gene rearrangement. (A) TCR gene rearrangement demonstrates monoclonal peak on TCR-β tube A (Table 1, patient 2). (B) TCR gene rearrangement demonstrates polyclonality on TCR-β tube C (Table 1, patient 3).

Fig. 2

Systemic T-cell lymphoproliferative disease (Table 1, patient 1). (A) Lymph node biopsy showed medium sized lymphocytes with moderate atypia showing positivity for CD3 (B) and Epstein-Barr virus-encoded early RNA using in situ hybridization (C).

Fig. 3

Epstein-Barr virus (EBV)-positive hemophagocytic lymphohistiocytosis (Table 1, patient 3). (A, B) (A) Liver biopsy shows sinusoidal and periportal lymphocytic infiltrates without significant atypia. (B) The majority of lymphocytes are positive for EBV-encoded early RNA (EBER) in situ hybridization. (C, D) After three months from liver biopsy, lymph node biopsy shows infiltration of medium sized atypical lymphocytes with many histiocytes (C). EBER is positive (D). (E, F) Immunohistochemical study reveals that the majority of infiltrated lymphocytes express CD3 (E) and CD8 (F).

Fig. 4

Chronic active Epstein-Barr virus (EBV) infection (Table 2, patient 5). (A) Perforated small intestine shows ulceration with granulation tissue. (B) Infiltrated cells are acute inflammatory cells and small lymphocytes without atypia. (C) EBV-encoded early RNA (EBER) is positive in small lymphocytes. (D) Double procedure for EBER using in situ hybridization (nuclear staining, brown) and immunostaining for CD8 (cytoplasmic staining, red) show EBER-positive cytotoxic T lymphocytes.

Table 1.

Clinicopathological findings of systemic T-cell lymphoproliferative disease and EBV-positive hemophagocytic lymphohistiocytosis

No.	Sex	Age (yr)	Symptom	On-set	Biopsy site	Hemophagocytic histiocytosis	Cell size/Atypia	EBV-PCR (copy/μL whole blood)	EBV-ISH	EBV serology	IHC	TCRy gene	Treatment	Follow-up	Course
Systemic T-cell LPD
1	F	7	Fever, cervical lymph node enlargement	2MA	LN,BM	Present	Medium/moderate atypia	42 (initial), 2.5-42	Positive	EB-VCA, lgG(+) EB-	CD3+	Monoclonal	VHR, L-Asp	3 mo	Dead
										VCA, IgM(-)	CD4<CD8
										EBV-EA(+)	CD56-
										EBNA(+)
2	M	43	Fever, splenomegaly	2MA	BM	Present	Small/mild atypia	142 (initial), 0-142	Positive	NC	CD3+	Monoclonal	IMVP-16/PD	2 mo	Dead
											CD4+
											CD8+
											CD56–
EBV-positive hemophagocytic lymphohistiocytosis
3	F	4	Fever, jaundice, hepatomegaly, leukocytopenia	2WA	LN, BM, liver	Present	Medium/severe atypia	506 (initial), 4.77-6,422	Positive	EB-VCA, igG(+)	CD3+	Polyclonal	106B, VHR	3 mo	Dead
										EB-VCA, lgM(+)	CD4-
										EBV-EA(+)	CD8+
										EBNA(-)	CD56–
4	M	10	Cervical lymph node enlargement, persistent fever, hepatosplenomegaly, LFT abnormality, pancytopenia, facial petechiae, gingival swelling	1MA	BM	Present	Medium/moderate atypia	5,810 (initial), 8.4-5, 810	Failed	NA	CD3+	No band	HLH-2004a	69 mo	Alive
											CD4-
											CD8+
											CD56-
5	F	20	Headache, fever, night sweat, abdominal pain, hepatosplenomegaly	3DA	BM	Present	Small/mild atypia	8.5	Positive	NA	CD3+	Polyclonal	CHOP	1 mo	Dead
											CD4<CD8
											CD56–
6	M	33	Fever	1MA	Liver	Present	Small/mild atypia	105.7	Positive	NA	CD3+	Polyclonal	Steroid	3 days	Dead
											CD4+CD8+
											CD56-
7	F	61	Fever, chill	4WA	Spleen, BM	Present	Small/mild atypia	NA	Positive	EB-VCA, igG(+)	CD3+	Polyclonal	Steroid	1 mo	Dead
										EB-VCA, lgM(-)	CD4+
										EBV-EA(-)	CDS-
										EBNA(+)	CD56–

Treatment regimen; VHR: prednisolone, cyclophosphamide, daunorubicin, vincristine, L-asparaginase, intrathecal methotrexate, L-Asp: L-asparaginase, IMVP-16/PD: ifosfamide, methotrexate, etoposide, prednisolone, 106B: prednisolone, cyclophosphamide, daunorubicin, vincristine, L-asparaginase, CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone.

LPD, lymphoproliferative disease; EBV, Epstein-Barr virus; PCR, polymerase chain reaction; ISH, in situ hybridization; IHC, immunohistochemistry; TCR, T-cell receptor; F, female; MA, months ago; LN, lymph node; BM, bone marrow; EB-VCA, EB viral capsid antigen; EBV-EA, EBV early antigen complex; EBNA, EBV nuclear antigen; M, male; WA, weeks ago; LFT, liver function test; NA, not available; DA, days ago.

^a HLH-94/2004: dexamethasone, cyclosporinA, intravenous Ig.

Table 2.

Clinicopathological findings of CAEBV infection

No.	Sex	Age (yr)	Symptom	On-set	Biopsy site	Hemophagocytic histiocytosis	Associated lymphoma	EBV-PCR (copy/μL whole blood)	EBV-ISH	EBV serology	IHC	TCRy gene	Treatment	Follow-up	Course
1	M	10	LFT abnormality, hepatosplenomeg-aly, multiple enlarged lymph node (posterior neck, axilla and inguinal area) mosquito-bite hypersentivity	2YA	LN, BM	Absent	Peripheral T-cell lymphoma	77.6 (initial), 71.24-2,936	Positive	EB-VCA, IgG(+)	CD3+	Monoclonal/monomorphic	106B	10 mo	Dead
										EB-VCA, IgM(–)
										EBV-EA(+)
										EBNA(+)
2	F	14	Fever, sore throat, IgA nephropathy, hydroa vacciniforme	Infancy	Skin, BM	Absent	T/NKcell lymphoma	NA	NA	NA	CD3+	NA	CHOP, ESHAP	18 mo	Dead
3	M	15	Nausea, weight loss, LFT abnormality, Herpes zoster infection	2MA	Liver, BM	Present	None	258.5 (initial), 22-258.5	Positive	EB-VCA, IgG(+)	CD3+	Monoclonal/monomorphic	HLH-2004a	7 mo	Dead
										EB-VCA, IgM(–)	CD4>CD8
										EBV-EA(±)	CD56–
										EBNA(+)
4	M	15	Mosquito-bite hypersensitivity, palpable neck mass, NK lymphocytosis	2WA	LN,BM	Absent	None	529.8 (initial), 40-529.8	Positive	EB-VCA, IgG(+)	CD3+	NA	ABVD	45 mo	Alive
										EB-VCA, IgM(–)	CD4+
										EBV-EA(+)	CD8+
										EBNA(+)	CD56–
5	M	16	Fever and skin lesion (4YA), bowel perforation (7YA) mosquito-bite hypersensitivity, NK lymphocytosis	Infancy	Skin, BM	Present	None	2,290 (initial), 7-2,290	Positive	EB-VCA, IgG(+)	CD3+	Polyclonal/polymorphic	HLH-2004a	46 mo	Alive
										EB-VCA, IgM(–)	CD4+
										EBV-EA(+)	CD8+
										EBNA(+)	CD56–
6	M	21	Mosquito-bite hypersensitivity, fever, epigastric pain, nausea, NK lymphocytosis	7MA	Liver, BM	Present	None	NA	NA	EB-VCA, IgG(+)	NC	NA	IMVP-16PD	3 mo	Dead
										EB-VCA, IgM(–)
										EBV-EA(±)
										EBNA(+)
7	M	21	Chorea movement, hepatosplenomegaly, severe oral ulcer, history of pneumonia, thrombocytopenia, NK lymphocytosis	2YA	Liver, BM	Present	None	29 (initial), 29-73.5	Positive	EB-VCA, IgG(+)	CD3+	Polyclonal (KIR: NK cells with clonality)	CHOP	10 mo	Alive (improved)
										EB-VCA, IgM(–)	CD4>CD8		ICE
										EBV-EA(–)	CD56+
										EBNA(+)
8	F	29	Fever, dizziness, nausea, hepatosplenomegaly, pancytopenia, LFT abnormality, diffuse lung infiltration	2WA	LN, lung, BM	Absent	None	189.2 (initial), 189.2-1,897	Positive	EB-VCA, IgG(+)	CD3+	Monoclonal/polymorphic	Self-limited	6 mo	Alive (persistent)
										EB-VCA, IgM(±)	CD4+
										EBV-EA(±)	CD8–
										EBNA(+)	CD56–
9	M	33	Fatigue, hepatosplenomegaly, NK lymphocytosis	7MA	Liver, BM	Present	None	3,446 (initial), 1,918.6-12,112	Positive	NA	CD3+	NA	Refuse	8 mo	Dead
											CD4<CD8
											CD56–
10	F	41	Fever, hepatomegaly, abdominal pain, cerebral infact	2YA	BM	Present	Medium/ mild atypia	1,231.8 (initial), 1,231.8-16,188	Positive	NA	CD3+	Polyclonal/polymorphic	HLH-94a	30 mo	Dead
											CD4–		CVP
											CD8+
											CD56–
11	M	44	LFT abnormality, hepatosplenomegaly, palpable neck mass	8MA	LN, liver	Absent	None	NA	Positive	EB-VCA, IgG(+)	CD3+	NA	Refuse	6 mo	Dead
										EB-VCA, IgM(-)	CD4+
										EBV-EA(+)	CD8+
										EBNA(+)	CD56–
12	F	59	Fever, myalgia, NK lymphocytosis	7MA	BM	Present	None	65.28 (initial), 36.6-2,934	Negative	NA	CD3+	No band	CVP, CHOP, IMVP-16/PD, VP	4 mo	Dead
											CD4–
											CD8+
											CD56+

Treatment regimen; 106B: prednisolone, cyclophosphamide, daunorubicin, vincristine, L-asparaginase, CHOP: cyclophosphamide, daunorubicin, vincristine, prednisolone, ESHAP: etoposide, methylprednisolone, high-dose cytarabine, cisplatin, ABVD: adriamycin, bleomycin, vinblastine, dacarbazine, IMVP-16/PD: ifosfamide, methotrexate, etoposide, prednisolone, ICE: ifosfamide, carboplatin, etoposide, CVP: cyclophosphamide, vincristine, prednisolone.

CAEBV, chronic active Epstein-Barr virus; EBV, Epstein-Barr virus; PCR, polymerase chain reaction; ISH, in situ hybridization; IHC, immunohistochemistry; TCR, T-cell receptor; M, male; LFT, liver function test; YA, years ago; LN, lymph node; BM, bone marrow; EB-VCA, EB viral capsid antigen; EBV-EA, EBV early antigen complex; EBNA, EBV nuclear antigen; F, female; NK, natural killer; NA, not available; MA, months ago; WA, weeks ago; KIR, killer cell immunoglobulin-like receptor.

^a HLH-94/2004: dexamethasone, cyclosporinA, intravenous Ig.

Figure & Data

References

Citations

Citations to this article as recorded by  

• An update on Epstein-Barr virus–and human T-lymphotropic virus type-1–induced cutaneous manifestations. CME Part II
  Alejandro A. Gru, Jose A. Plaza, Jose A. Sanches, Denis Miyashiro, Omar P. Sangueza, Francisco Bravo Puccio, Sonia Toussaint, J. Martin Sangueza
  Journal of the American Academy of Dermatology.2023; 88(5): 983.     CrossRef
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
  Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle, Iguaracyra Barreto de Oliveira Araujo, Emilio Berti, Govind Bhagat, Anita Maria Borges, Daniel Boyer, Mariarita Calaminici, Amy Chadburn, John K. C. Chan, Wah Cheuk, Wee-Joo Chng,
  Leukemia.2022; 36(7): 1720.     CrossRef
• Chronic active Epstein–Barr virus enteritis: A literature review
  Yang Shen, Yu Fang Wang
  Journal of Digestive Diseases.2022; 23(5-6): 248.     CrossRef
• EBV-Associated Lymphoproliferative Disorders
  Young Hyeh Ko
  Clinical Pediatric Hematology-Oncology.2021; 28(1): 14.     CrossRef
• Clinicopathologic findings of chronic active Epstein–Barr virus infection in adults: A single-center retrospective study in China
  Jing Lin, Haicong Wu, Lei Gu, Xia Wu, Miaofang Su, Haiyan Lin, Bang Liu, Jiaolong Zheng, Xuan Mei, Dongliang Li
  Clinical and Experimental Medicine.2021; 21(3): 369.     CrossRef
• Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein–Barr virus infection
  Honghao Ma, Liping Zhang, Ang Wei, Jun Yang, Dong Wang, Qing Zhang, Yunze Zhao, Sitong Chen, Hongyun Lian, Li Zhang, Chunju Zhou, Maoquan Qin, Zhigang Li, Tianyou Wang, Rui Zhang
  Orphanet Journal of Rare Diseases.2021;[Epub]     CrossRef
• Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting
  Jeffrey I. Cohen, Keiji Iwatsuki, Young-Hyeh Ko, Hiroshi Kimura, Irini Manoli, Koichi Ohshima, Stefania Pittaluga, Leticia Quintanilla-Martinez, Elaine S. Jaffe
  Leukemia & Lymphoma.2020; 61(4): 808.     CrossRef
• EBV-positive T/NK-associated lymphoproliferative disorders of childhood: A complete autopsy report
  JonathanY Keow, WilliamM Stecho, AaronR Haig, NikhilA Sangle
  Indian Journal of Pathology and Microbiology.2020; 63(1): 78.     CrossRef
• Chronic active Epstein‐Barr virus infection: A heterogeneous entity requiring a high index of suspicion for diagnosis
  Sarah L. Ondrejka, Eric D. Hsi
  International Journal of Laboratory Hematology.2020; 42(S1): 99.     CrossRef
• Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases
  Wook Youn Kim, Ivonne A. Montes-Mojarro, Falko Fend, Leticia Quintanilla-Martinez
  Frontiers in Pediatrics.2019;[Epub]     CrossRef
• A clinicopathologic study of the spectrum of systemic forms of EBV‐associated T‐cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America
  Amy M. Coffey, Annisa Lewis, Andrea N. Marcogliese, M. Tarek Elghetany, Jyotinder N. Punia, Chung‐Che Chang, Carl E. Allen, Kenneth L. McClain, Amos S. Gaikwad, Nader Kim El‐Mallawany, Choladda V. Curry
  Pediatric Blood & Cancer.2019;[Epub]     CrossRef
• Unusual lymphoid malignancy and treatment response in two children with Down syndrome
  Ashley Geerlinks, Jennifer Keis, Bo Ngan, Amer Shammas, Reza Vali, Johann Hitzler
  Pediatric Blood & Cancer.2019;[Epub]     CrossRef
• EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts
  Stefan Dojcinov, Falko Fend, Leticia Quintanilla-Martinez
  Pathogens.2018; 7(1): 28.     CrossRef
• Cutaneous Hematolymphoid and Histiocytic Proliferations in Children
  Alejandro A Gru, Louis P Dehner
  Pediatric and Developmental Pathology.2018; 21(2): 208.     CrossRef
• Clinicopathological categorization of Epstein–Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications
  Jin Ho Paik, Ji-Young Choe, Hyojin Kim, Jeong-Ok Lee, Hyoung Jin Kang, Hee Young Shin, Dong Soon Lee, Dae Seog Heo, Chul-Woo Kim, Kwang-Hyun Cho, Tae Min Kim, Yoon Kyung Jeon
  Leukemia & Lymphoma.2017; 58(1): 53.     CrossRef
• Cutaneous EBV-related lymphoproliferative disorders
  Alejandro A. Gru, Elaine S. Jaffe
  Seminars in Diagnostic Pathology.2017; 34(1): 60.     CrossRef
• T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting
  Dita Gratzinger, Daphne de Jong, Elaine S. Jaffe, Amy Chadburn, John K. C. Chan, John R. Goodlad, Jonathan Said, Yasodha Natkunam
  American Journal of Clinical Pathology.2017; 147(2): 188.     CrossRef
• Systemic Epstein-Barr Virus-positive T-Cell Lymphoproliferative Disease of Childhood With Good Response to Steroid Therapy
  Do-Hoon Kim, Myungshin Kim, Yonggoo Kim, Kyungja Han, Eunhee Han, Jae Wook Lee, Nack-Gyun Chung, Bin Cho
  Journal of Pediatric Hematology/Oncology.2017; 39(8): e497.     CrossRef
• Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease
  Paibel Aguayo-Hiraldo, Reuben Arasaratnam, Rayne H. Rouce
  Boletín Médico del Hospital Infantil de México.2016; 73(1): 31.     CrossRef
• Severe Epstein–Barr virus infection in primary immunodeficiency and the normal host
  Austen J. J. Worth, Charlotte J. Houldcroft, Claire Booth
  British Journal of Haematology.2016; 175(4): 559.     CrossRef
• Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease
  Paibel Aguayo-Hiraldo, Reuben Arasaratnam, Rayne H. Rouce
  Boletín Médico Del Hospital Infantil de México (English Edition).2016; 73(1): 31.     CrossRef
• Epstein-Barr Virus–Associated Lymphomas
  Ewelina Grywalska, Jacek Rolinski
  Seminars in Oncology.2015; 42(2): 291.     CrossRef
• Epstein–Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype
  Siok-Bian Ng, Koichi Ohshima, Viknesvaran Selvarajan, Gaofeng Huang, Shoa-Nian Choo, Hiroaki Miyoshi, Norio Shimizu, Renji Reghunathan, Hsin-Chieh Chua, Allen Eng-Juh Yeoh, Thuan-Chong Quah, Liang-Piu Koh, Poh-Lin Tan, Wee-Joo Chng
  Leukemia & Lymphoma.2015; 56(8): 2408.     CrossRef
• Hemophagocytic syndromes — An update
  Gritta E. Janka, Kai Lehmberg
  Blood Reviews.2014; 28(4): 135.     CrossRef
• Epstein–Barr virus‐associated T/natural killer‐cell lymphoproliferative disorders
  Sanghui Park, Young H. Ko
  The Journal of Dermatology.2014; 41(1): 29.     CrossRef